Skip to main content
SpringerLink
Log in

Clinical Perspectives on Bone Quality in Osteoporosis

Effects of Drug Therapy

  • Current Opinion
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Treatment of primary osteoporosis has advanced dramatically during the past decade, with more therapeutic options being available now than at any other time. Anti-resorptive (anti-catabolic) drugs have been prominent in the treatment of osteoporosis for decades. However, over time, several clinical observations made during use of these agents have challenged the prevailing dogma about mechanisms of drug action, changes in bone density and fracture reduction during treatment. It has become clear that changes in bone density are only a small part of the explanation for the dramatic reduction of fractures with treatment. From this paradox developed the notion of ‘bone quality’ — an operational term describing a number of characteristics that enable bone to resist fracturing. This article reviews this concept from a clinical perspective. It discusses the historical paradoxes found in clinical practice that have led to this notion, identifies the major areas of bone physiology circumscribed by the concept and focuses on present therapies and their effects on bone quality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III
Fig. 2

Similar content being viewed by others

References

  1. Felsenberg D, Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Therapeut 2005; 27: 1–11

    Article  Google Scholar 

  2. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002; 288(15): 1889–97

    Article  PubMed  Google Scholar 

  3. Riggs LB, Hodgson SF, O’Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802–9

    Article  PubMed  CAS  Google Scholar 

  4. Kleerekorper M, Peterson E, Nelson DA, et al. A randomised trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int 1991; 1: 155–62

    Article  Google Scholar 

  5. Riggs BL, O’Fallon WM, Lane A, et al. Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res 1994; 9: 265–75

    Article  PubMed  CAS  Google Scholar 

  6. Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002; 17: 1–10

    Article  PubMed  CAS  Google Scholar 

  7. Harris ST, Watts MB, Genant HK, et al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999; 282: 1344–52

    Article  PubMed  CAS  Google Scholar 

  8. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine density and reduction in risk of vertebral fracture during treatment with antiresorption drugs. Am J Med 2002; 112: 281–9

    Article  PubMed  CAS  Google Scholar 

  9. Chapurlat RD, Palermo L, Ramsay P, et al. Risk of fractures among women who lose bone density during treatment with alendronate: the Fracture Intervention Trial. Osteoporos Int 2002; 16: 842–8

    Article  Google Scholar 

  10. Cranney A, Guyatt G, Griffith L, et al. Summary of metaanalysis of therapies for postmenopausal osteoporosis. Endocrine Rev 2002; 23: 570–8

    Article  CAS  Google Scholar 

  11. Marcic M, Adachi J, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Int Med 2002; 162: 1140–3

    Article  Google Scholar 

  12. Watts NB, Josse RG, Hamdy RC, et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2003; 88: 542–9

    Article  PubMed  CAS  Google Scholar 

  13. Seeman E, Delmas PD. Bone quality: the material and structural basis of bone strength and fragility. N Engl J Med 2006; 354: 2250–61

    Article  PubMed  CAS  Google Scholar 

  14. Bouxsein ML, Karasik D. Bone geometry and skeletal fragility. Curr Osteoporos Rep 2006 Jun; 4(2): 49–56

    Article  PubMed  Google Scholar 

  15. Brownbill RA, Ilich JZ. Hip geometry and its role in fracture: what do we know so far? Curr Osteoporos Rep 2003; 1: 25–31

    Article  PubMed  Google Scholar 

  16. Pal GP, Routai RV. Architecture of the cancellous bone of the human talus. Anat Rec 1998; 252: 185–93

    Article  PubMed  CAS  Google Scholar 

  17. Chai BF, Tang XM, Zhou WR. Arch structure of trabeculae of the upper femoral end and its biochemical significance in hip fractures. Chinese Med J 1994; 107: 505–11

    CAS  Google Scholar 

  18. Dalle Carbonare L, Bertoldo F, Valenti MT, et al. Histomorphometric analysis of glucocorticoid-induced osteoporosis. Micron 2005; 36: 645–52

    Article  Google Scholar 

  19. Aaron JE, Francis RM, Peacock M, et al. Contrasting microanatomy of idiopathic and corticosteroid-induced osteoporosis. Clin Orthoped 1989; 243: 294–305

    Google Scholar 

  20. Genant HK, Delmas PD, Chen P, et al. Severity of vertebral fracture reflects deterioration of bone microarchitecture. Osteoporos Int 2007 Jan; 18(1): 69–76

    Article  PubMed  CAS  Google Scholar 

  21. Teitelbaum SL. Pathological manifestations of osteomalacia and rickets. Clin Endocrinol Metab 1980; 9: 43–62

    Article  PubMed  CAS  Google Scholar 

  22. Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med 2004; 351: 2839–49

    Article  PubMed  Google Scholar 

  23. Knott L, Bailey AJ. Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance. Bone 1998; 22(3): 181–7

    Article  PubMed  CAS  Google Scholar 

  24. Currey JD. The many adaptations of bone. J Biomech 2003; 36: 1487–95

    Article  PubMed  CAS  Google Scholar 

  25. Currey JD. Bone architecture and fracture. Curr Osteoporos Rep 2005; 3: 52–6

    Article  PubMed  Google Scholar 

  26. Wang X, Li X, Shen X, et al. Age-related changes of non-calcified collagen in human cortical bone. Ann Biomed Eng 2003; 31: 1365–71

    Article  PubMed  Google Scholar 

  27. Dominguez LJ, Barbagallo M, Moro L. Collagen overglycosylation: a biochemical feature that may contribute to bone quality. Biochem Biophys Res Comm 2005; 330: 1–4

    Article  PubMed  CAS  Google Scholar 

  28. Nimni BS, Bernick S, Paule W, et al. Changes in the ratio of non-calcified to calcified collagen in human vertebrae with advancing age. Connect Tissue Res 1993; 2: 133–40

    Article  Google Scholar 

  29. Zioupos P, Currey JD, Hamer AJ. The role of collagen in the declining mechanical properties of aging cortical bone. J Biomed Mater Res 1999; 2: 108–16

    Article  Google Scholar 

  30. Vashishth D. Collagen glycation and its role in fracture properties of bone. J Musculoskelet Neuronal Interact 2005; 5: 316

    PubMed  CAS  Google Scholar 

  31. O’Brien FJ, Brennan O, Kennedy OD, et al. Microcracks in cortical bone: how do they affect bone biology? Curr Osteoporos Rep 2005; 3: 39–45

    Article  PubMed  Google Scholar 

  32. Lee TC, Mohsin S, Taylor D, et al. Detecting microdamage in bone. J Anat 2003; 203: 161–72

    Article  PubMed  CAS  Google Scholar 

  33. Lofman O, Magnusson P, Toss G, et al. Common biochemical markers of bone turnover predict future bone loss: a 5-year follow up study. Clin Chim Acta 2005; 356: 67–75

    Article  PubMed  Google Scholar 

  34. Miller PD, Hochberg MC, Wehren LE, et al. How useful are measures of BMD and bone turnover? Curr Med Res Opin 2005; 21: 545–53

    Article  PubMed  Google Scholar 

  35. Riggs BL, Melton III LJ. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002; 17: 11–4

    Article  PubMed  Google Scholar 

  36. Adachi JD, Rizzoli R, Boonen S, et al. Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data. Aging Clin Exp Res 2005; 17: 150–6

    PubMed  CAS  Google Scholar 

  37. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000; 85: 4118–24

    Article  PubMed  CAS  Google Scholar 

  38. Heaney RP. The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 1994; 9: 1515–23

    Article  PubMed  CAS  Google Scholar 

  39. Gonnelli S, Cepollaro C, Ponrelli C, et al. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J Bone Miner Res 1997; 12: 624–31

    Article  PubMed  CAS  Google Scholar 

  40. Seibel MJ, Naganathan V, Barton I, et al. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 2004; 19: 323–9

    Article  PubMed  CAS  Google Scholar 

  41. Bauer DC, Garnero P, Hochberg MC, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the Fracture Intervention Trial. J Bone Miner Res 2006; 21: 292–9

    Article  PubMed  CAS  Google Scholar 

  42. Beck TJ, Stone KL, Oreskovic TL, et al. Effects of current and discontinued estrogen replacement therapy on hip structural geometry: the study of osteoporotic fractures. J Bone Miner Res 2001; 16: 2103–10

    Article  PubMed  CAS  Google Scholar 

  43. Boivin G, Vedi S, Puride DW, et al. Influence of estrogen therapy at conventional and high doses on the degree of mineralization of iliac bone tissue: a quantitative microradiographic analysis in postmenopausal women. Bone 2005; 36: 562–7

    Article  PubMed  CAS  Google Scholar 

  44. Borah B, Ritman EL, Dufresne TE, et al. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone 2005; 37: 1–9

    Article  PubMed  CAS  Google Scholar 

  45. Recker R, Masarachia P, Santora A, et al. Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin 2005; 21: 185–94

    Article  PubMed  CAS  Google Scholar 

  46. Meunier PJ, Arlot M, Chavasieux P, et al. The effects of alendronate on bone turnover and bone quality. Int J Clin Pract 1999; 101 Suppl.: 14–7

    CAS  Google Scholar 

  47. Eriksen EF, Meisen F, Sod E, et al. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 2002; 31: 620–5

    Article  PubMed  CAS  Google Scholar 

  48. Mueller R, Hannan M, Smith SY, et al. Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. J Bone Miner Res 2004; 19: 1787–96

    Article  Google Scholar 

  49. Chesnut III CH, Majumdar S, Newitt DC, et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imagining: results from the Quest study. J Bone Miner Res 2005; 20: 1548–61

    Article  PubMed  CAS  Google Scholar 

  50. Allen MR, Iwata K, Phipps R, et al. Alterations in canine vertebral bone turnover, microdamage accumulation, and biochemical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006; 39: 872–9

    Article  PubMed  CAS  Google Scholar 

  51. Fischer KJ, Vijoren TH, Ney S, et al. Mechanical evaluation of bone samples following alendronate therapy in healthy male dogs. J Biomed Mater Res B Appl Biomater 2006; 76b: 143–8

    Article  CAS  Google Scholar 

  52. Jerome CP, Burr DB, Van Bibber T, et al. Treatment with human parathyroid hormone (1—34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 2001; 28: 150–9

    Article  PubMed  CAS  Google Scholar 

  53. Paschalis EP, Burr DB, Mendelsohn R, et al. Bone mineral and collagen quality in humeri of ovariectomized cynomolgus monkeys given rhPTH (1–34) for 18 months. J Bone Miner Res 2003; 18: 769–75

    Article  PubMed  CAS  Google Scholar 

  54. Paschalis EP, Glass EV, Donley DW, et al. Bone and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial. J Clin Endocrinol Metab 2005; 90: 4644–9

    Article  PubMed  CAS  Google Scholar 

  55. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fracture and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434–41

    Article  PubMed  CAS  Google Scholar 

  56. Waarsing JH, Day JS, Weinans H. Longitudinal micro-CT scans to evaluate bone architecture. J Musculoskelet Neuronal Interact 2005; 5: 310–2

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this article. The author has no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Departments of Endocrinology, Diabetes, and Metabolism, Biomedical Engineering, Orthopedic Research Council, Metabolic Bone Center, Center for Space Medicine, Cleveland Clinic, Cleveland, Ohio, USA

    Angelo A. Licata

Authors
  1. Angelo A. Licata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angelo A. Licata.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Licata, A.A. Clinical Perspectives on Bone Quality in Osteoporosis. Drugs Aging 24, 529–535 (2007). https://doi.org/10.2165/00002512-200724070-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200724070-00001

Keywords

Search

Navigation